ENDRA Life Sciences (NASDAQ:NDRA) Upgraded at Zacks Investment Research

ENDRA Life Sciences (NASDAQ:NDRAGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “ENDRA Life Sciences Inc. is a developer of enhanced ultrasound technologies. ENDRA Life Sciences Inc. is based in Ann Arbor, United States. “

Separately, HC Wainwright decreased their price objective on shares of ENDRA Life Sciences from $6.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, April 7th.

Shares of NDRA opened at $0.27 on Wednesday. The stock has a 50 day moving average of $0.36. ENDRA Life Sciences has a 52 week low of $0.22 and a 52 week high of $2.44. The company has a market cap of $11.72 million, a PE ratio of -0.98 and a beta of 1.40.

ENDRA Life Sciences (NASDAQ:NDRAGet Rating) last issued its quarterly earnings results on Wednesday, March 30th. The company reported ($0.07) EPS for the quarter. During the same period in the previous year, the company earned ($0.10) earnings per share. As a group, research analysts forecast that ENDRA Life Sciences will post -0.26 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in ENDRA Life Sciences by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 323,679 shares of the company’s stock worth $559,000 after acquiring an additional 7,197 shares during the last quarter. Royal Bank of Canada raised its holdings in ENDRA Life Sciences by 65.3% in the 2nd quarter. Royal Bank of Canada now owns 25,310 shares of the company’s stock worth $55,000 after acquiring an additional 10,000 shares during the last quarter. Morgan Stanley raised its holdings in ENDRA Life Sciences by 5.3% in the 2nd quarter. Morgan Stanley now owns 232,312 shares of the company’s stock worth $506,000 after acquiring an additional 11,678 shares during the last quarter. Citadel Advisors LLC purchased a new stake in ENDRA Life Sciences during the 3rd quarter valued at $26,000. Finally, Raymond James & Associates purchased a new stake in ENDRA Life Sciences during the 4th quarter valued at $49,000. Institutional investors own 10.03% of the company’s stock.

About ENDRA Life Sciences (Get Rating)

ENDRA Life Sciences Inc develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion.

Further Reading

Get a free copy of the Zacks research report on ENDRA Life Sciences (NDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.